By Daniel Horowitz
For nearly half a century after the catastrophic 1967 trial, the U.S. government failed to approve a safe and effective RSV vaccine. Then came the COVID-19 debacle 鈥 and suddenly, we鈥檙e supposed to believe the science caught up. As if by magic, after the mRNA disaster and its lingering questions, federal agencies now bless an endless stream of RSV shots for children and adults alike.
Never mind that just two years ago, Anthony Fauci co-authored a paper admitting that safe RSV vaccine development faced 鈥渕any and complex鈥 challenges. He cited risks like antigenic drift and called for 鈥渙utside-the-box鈥 thinking to make next-generation vaccines possible.
If Kennedy truly doubts the safety of older vaccines, why would his handpicked advisers endorse new injections for a virus that rarely warrants immunization?
Apparently, that box got checked quickly 鈥 at least according to the Centers for Disease Control and Prevention.
The CDC鈥檚 Advisory Committee on Immunization Practices voted last month to approve Merck鈥檚